has received honoraria for consulting, lectures from Abbott Laboratories, Amgen, Astra Zeneca, Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim, Cargene, CRISPR, Daiichi Sankyo, Eli Lilly Company, Esperion, Kowa, New Amsterdam Pharma, Novartis Corporation, Novo Nordisk, Pfizer, Regeneron, Sanofi, SCRIBE, Silence Therapeutics, and VAXXINITY. This study is funded by Daiichi Sankyo Europe GmbH, Munich, Germany.Ĭardiovascular disease Cohort study High cardiovascular risk LDL cholesterol Lipid-lowering therapy Real-world evidence. Further efforts are needed to achieve current guideline-recommended LDL-C goals.Ĭ Identifier: NCT04271280. Contributory factors may include CV risk underestimation and underutilization of combination therapies. Median (interquartile range ) LDL-C was 2.1 (1.6, 3.0) mmol/L (82 mg/dL), with 20.1% of patients achieving risk-based LDL-C goals as per the 2019 ESC/EAS guidelines.Īt the time of study enrolment, 80% of high- and very high-risk patients failed to achieve 2019 ESC/EAS guidelines LDL-C goals. Overall, 21.8% of patients had no documented LLTs, 54.2% were receiving monotherapy and 24.0% combination LLT. However, centrally re-assessed CV risk based on 2019 ESC/EAS guidelines suggested 6.5% (308/4706) and 91.0% (4284/4706) were high- and very high-risk patients, respectively. Physicians reported using 2019 ESC/EAS guidelines as a basis for CV risk classification in 52.0% (4706/9044) of patients (overall: high risk 29.2% very high risk 70.8%). Of 9602 enrolled patients, 9044 with complete data were included (mean age: 65.3 ± 10.9 years 72.6% male).
Whether the treatment landscape has evolved, or gaps persist remains of interest.īaseline data are presented from SANTORINI, an observational, prospective study that documents the use of lipid-lowering therapies (LLTs) in patients ≥18 years at high or very high CV risk between 20 across primary and secondary care settings in 14 European countries. 18 Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy.Įuropean data pre-2019 suggest statin monotherapy is the most common approach to lipid management for preventing cardiovascular (CV) events, resulting in only one-fifth of high- and very high-risk patients achieving the 2019 ESC/EAS recommended low-density lipoprotein cholesterol (LDL-C) goals.17 Department of Vascular Medicine, University Medical Center Utrecht, Utrecht, the Netherlands.16 Division of Endocrinology and Diabetology, Department of Medicine, Medical University of Graz, Graz, Austria.15 Center for Life Course Health Research, University of Oulu, Oulu, Finland.14 Department of Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.13 Department of Internal Medicine and Pediatrics, Ghent University and Ghent University Hospital, Ghent, Belgium.12 Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland.11 Department of Internal Medicine, La Paz-Carlos III Hospital, Madrid, Spain.10 Department of Cardiology, University Hospital Leipzig, Leipzig, Germany.9 Department of Cardiology and INSERM UMR 1295, Toulouse Rangueil University Hospital, Toulouse University School of Medicine, Toulouse, France.8 Department of Medicine, Karolinska University Hospital, Stockholm, Sweden.7 Sandwell and West Birmingham NHS Trust, Birmingham City Hospital, Institute of Cardiovascular Sciences, University of Birmingham, and Aston Medical School, Birmingham, UK.6 Department of Translational and Precision Medicine, Sapienza Università di Roma, Rome, Italy.5 Advanced Heart Failure and Heart Transplantation Unit, Heart Institute, Carnaxide, Portugal.4 Biostatistics and Data Management, Daiichi Sankyo Europe, Munich, Germany.3 Health Economics and Outcomes Research, Daiichi Sankyo Europe, Munich, Germany.2 Medical Affairs, Daiichi Sankyo Europe, Munich, Germany.1 Imperial Centre for Cardiovascular Disease Prevention, ICTU-Global, Imperial College London, London, UK.
0 kommentar(er)
